EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation



    AMSTERDAM, Sept. 22 /CNW/ - Kiadis Pharma announced today that its lead
product ATIR(TM) has been granted orphan drug designation (ODD) by the
European Medicines Agency (EMEA) for the prevention of acute Graft versus Host
Disease (GvHD) following an allogeneic bone marrow transplantation.
    "Following the orphan drug designation granted by the FDA for our lead
product ATIR(TM), this is another important milestone in the development of
ATIR(TM) as a novel approach which may enable a safe and potentially
life-saving mismatched bone marrow transplantation as a treatment option for
end-stage blood cancer patients" says Dr. Manja Bouman, Chief Executive
Officer of Kiadis Pharma.
    The EMEA's orphan drug designation is reserved for new therapies being
developed to treat life-threatening or chronically debilitating diseases or
conditions that are relatively rare in the European Union and for which no
satisfactory therapy is available. The orphan drug designation provides for
incentives to support research and development, exemption from user fees and a
ten-year period of market exclusivity in the European Union after product
approval.
    For the complete press release please go to: http://www.kiadis.com/news

    About Kiadis Pharma

    Kiadis Pharma is an oncology focused pharmaceutical development company
with three products in different phases of clinical development. The company
develops products that offer novel treatment options for terminally ill cancer
patients and address significant unmet medical needs. The key focus indication
for Kiadis Pharma is limitations and complications of bone marrow
transplantation procedures performed in blood cancer patients. Kiadis Pharma
is headquartered in Amsterdam, The Netherlands with facilities in Groningen,
The Netherlands and Montreal, Canada. For more information about Kiadis
Pharma, please visit http://www.kiadis.com.





For further information:

For further information: Kiadis Pharma B.V., Eefje Simpelaar, Director
Communications, Email: e.simpelaar@kiadis.com, Tel: +31-20-3140250, Mob
+31-6-10829344.

Organization Profile

KIADIS PHARMA

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890